NERVGEN PHARMA CORP.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2025 · Filed Mar 31, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.3 · 2025 ATM Program
2025 ATM Program
As of the date of this report, we have raised total net proceeds of approximately $2.1 million under the ATM Program, which has been used to fund ongoing operations and working capital requirements. As disclosed in our prospectus supplement dated December 19, 2024, the principal business objectives that management expects to accomplish using the net proceeds from the ATM Program, are to fund general corporate purposes including to fund ongoing operations and/or working capital requirements, to repay indebtedness outstanding from time to time, to complete future acquisitions, to fund research and development, intellectual property development, preclinical expenses, or for other corporate purposes. We have broad discretion with respect to the actual use of the net proceeds from the ATM Program.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.